Valeant Launches Lumify OTC Eye Drops With Vision Of Better Days As Bausch

Lumify eye drops, the first OTC brimonidine tartrate ophthalmic solution 0.025% in the US, will reach stores in late May. Corporate name change, says CEO Joseph Papa, shows Valeant is "beginning to turn the page away from legacy issues that have been headwinds over the past few years."

Five years after acquiring Bausch & Lomb Inc. and a day after launching a US ophthalmic OTC switch for the brand, Valeant Pharmaceuticals International Inc. will make Bausch its corporate name in another step to improve its image in the pharma and consumer health sectors.

Valeant on May 8 released its first-quarter results and disclosed its pending name change to Bausch Health Companies Inc. after...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health